Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

This phase 2b trial of a short interfering RNA that targets ANGPTL3 showed substantive dose-dependent lowering of triglyceride levels.

​   The New England Journal of Medicine: Search Results in Cardiology